Patents by Inventor Bulent Mutus

Bulent Mutus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9522260
    Abstract: A stable delivery system for the therapeutic release and application of nitric oxide to a patient suffering from a cutaneous injury or wound includes a S-nitrosothiol and transition element nanoparticles. The transition metal nanoparticles are selected to react with the S-nitrosothiol to release and diffuse nitric oxide into the injury or wound.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: December 20, 2016
    Assignee: University of Windsor
    Inventors: Bulent Mutus, Arthur Jarosz, Adam Faccenda, Xueji Zhang
  • Publication number: 20120184052
    Abstract: A method of rapidly and accurately identifying and analyzing thiol proteins in a sample using gold nanoparticles. Disclosed are embodiments of a flow device for isolation, fractionation and subsequent instrumental analysis of thiol containing proteins from various samples or tissue sources using gold nanoparticles. Also disclosed are embodiments of a flow device for detecting, isolating and fractionating S-nitrosated proteins and peptides for subsequent analysis, including identification of S-nitrosation sites.
    Type: Application
    Filed: September 28, 2010
    Publication date: July 19, 2012
    Applicant: WORLD PRECISION INSTRUMENTS INC.
    Inventors: Xueji Zhang, Bulent Mutus
  • Publication number: 20110086363
    Abstract: Adhesion of platelets to blood vessel walls is the first step that promotes arrest of bleeding by interaction of the platelet receptors with various extracellular matrix proteins that become exposed on vascular injury. A flow chamber is provided for use in analyzing or studying platelet function, in whole blood, either as part of a batch process or in real time. In the flow chambers, an inert polydimethylsiloxane (PDMS) surface is plasma-activated and a homobifunctional cross-linker is used to immobilize platelet-binding proteins onto a chamber wall surface. Immobilized collagen and fibrinogen may thus be assayed by continuously monitoring the adhesion of ADP and Ca2+ activated platelets from a subject, such as a patient having normal or type 2 diabetes (T2D). The flow chamber provides a simplified and robust method for the construction flow chambers which enable the kinetic monitoring of platelet adhesion in whole blood.
    Type: Application
    Filed: October 5, 2010
    Publication date: April 14, 2011
    Inventors: Bulent Mutus, Edward C.J. Carriveau, Harmanpreet Kaur